No Data
The main shareholder of West Point Pharmaceutical (301130.SZ), Guotou Gaoke and its concerted actors have cumulatively reduced their shareholding by 1.03%.
West Point Pharmaceutical (301130.SZ) announced that the shareholder holding more than 5% of the company is China Investment Corporation High Technology Investment Co., Ltd.
Western Pharmaceutical (301130.SZ): Approved traditional chinese medicine products include Xin Nao Kang capsules and others.
On November 26, Gelong Hui reported that Western Point Pharmaceutical (301130.SZ) stated on the investor interaction platform that the company's approved traditional chinese medicine products include Xinnaokang capsules, Hepatitis B detoxification capsules, Hepatitis B supportive capsules, Glycemic control capsules, and Sanqi tablets, among others. Since its establishment, the company has been committed to enhancing its brand value through initiatives such as product positioning, product quality, continuous innovation and development, and intellectual property protection.
Chinese Drug Regulator Accepts Jilin Province Xidian Pharma's Application to Change Alzheimer Drug's Authorization Holder; Shares Down 3%
Western medicine (301130.SZ): The company's approved pharmaceutical list does not include folic acid active pharmaceutical ingredient and folic acid tablets
On November 22, Gelonghui announced that Western Point Pharmaceuticals (301130.SZ) stated on the investor interaction platform that the approved pharmaceutical list of our company does not include active pharmaceutical ingredients of folic acid or folic acid tablets.
Western Point Pharmaceutical (301130.SZ): The application for the transfer of the pharmaceutical上市许可 holder has been accepted.
West Point Pharmaceuticals (301130.SZ) announced that the company recently received a certification from the National Medical Products Administration for the pharmaceutical of L-tartaric acid...
West Pharmaceutical (301130.SZ): Guotou Gaoki and Hangzhou Chuanghe plan to collectively reduce their shareholding by no more than 3%.
On October 28, Gelonhui reported that XiDian Pharmaceuticals (301130.SZ) announced that Guotou Gaokex and Hangzhou Chuanghe planned to sharehold a cumulative total of no more than 2,294,700 shares, not exceeding 3% of the company's total share capital (excluding repurchases). Among them, within three months after 15 trading days from the date of this announcement, they will sharehold a total of no more than 764,900 shares through centralized auction trading, not exceeding 1% of the company's total share capital (excluding repurchases); within three months after 15 trading days from the date of this announcement, they will sharehold a total of no more than 1,529,800 shares through block trade, not exceeding the company's total share capital
No Data
No Data